An anti-CD38 human IgG1κ monoclonal antibody that binds CD38 on antibody-secreting plasma cells and plasmablasts, inducing depletion via ADCC, CDC, and apoptosis and modulating immune responses to lower antiphospholipid antibody titers and improve thrombocytopenia.
Daratumumab is a human IgG1κ monoclonal antibody that binds CD38 on plasma cells, plasmablasts, and other CD38+ cells, inducing cell death via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and apoptosis; it also depletes CD38+ immunoregulatory cells, thereby modulating immune responses and reducing pathogenic antibody production.
YES
DIRECT
Daratumumab binds CD38 on target cells and triggers Fc-mediated killing—ADCC by NK cells, CDC via complement, and ADCP by macrophages—and can also induce apoptosis upon binding/crosslinking.
Monoclonal antibody targeting HER2/ERBB2; inhibits signaling and mediates ADCC.
Humanized monoclonal antibody that binds HER2/ERBB2 on tumor cells, inhibits HER2 signaling and dimerization, and induces antibody‑dependent cellular cytotoxicity (ADCC) against HER2‑overexpressing cells.
YES
DIRECT
Trastuzumab binds HER2 on tumor cells and recruits FcγR-expressing immune effectors (e.g., NK cells) to mediate antibody-dependent cellular cytotoxicity, with some complement-mediated lysis; this kills HER2+ cells.
Humanized monoclonal antibody against HER2 that binds the extracellular dimerization domain (subdomain II), blocking ligand-dependent HER2 heterodimerization—especially HER2:HER3—thereby inhibiting downstream PI3K/AKT and MAPK signaling, reducing proliferation and promoting tumor cell death; complements trastuzumab.
YES
DIRECT
Pertuzumab binds HER2, blocks HER2:HER3 signaling to promote apoptosis, and its IgG1 Fc engages FcγR-bearing effector cells (e.g., NK cells) to mediate ADCC against HER2+ cells.
Trop-2–targeted antibody-drug conjugate consisting of the humanized anti–Trop-2 mAb (hRS7) linked via a hydrolyzable linker to SN-38 (active metabolite of irinotecan), delivering SN-38 to Trop-2–expressing tumor cells to induce DNA damage and cell death with a bystander effect.
Humanized anti–Trop-2 monoclonal antibody linked via a hydrolyzable linker to SN-38 (topoisomerase I inhibitor); binds Trop-2 on tumor cells, is internalized and cleaved to release SN-38, which stabilizes Topo I–DNA complexes to induce DNA damage and apoptosis, with a bystander killing effect.
YES
DIRECT
Antibody–drug conjugate binds TROP2, is internalized, and releases SN-38 (topoisomerase I inhibitor) causing DNA damage and apoptosis; also enables bystander killing.
Trop-2–targeted antibody-drug conjugate consisting of the humanized anti–Trop-2 mAb (hRS7) linked via a hydrolyzable linker to SN-38 (active metabolite of irinotecan), delivering SN-38 to Trop-2–expressing tumor cells to induce DNA damage and cell death with a bystander effect.
Humanized anti–Trop-2 monoclonal antibody linked via a hydrolyzable linker to SN-38 (topoisomerase I inhibitor); binds Trop-2 on tumor cells, is internalized and cleaved to release SN-38, which stabilizes Topo I–DNA complexes to induce DNA damage and apoptosis, with a bystander killing effect.
YES
INDIRECT
After Trop-2–mediated uptake (and bystander diffusion), the SN-38 payload inhibits topoisomerase I, stabilizing Topo I–DNA complexes and causing DNA damage and apoptosis; cells are not selected by Topo I expression itself.